Noxopharm Limited
NOXOF
Other OTC0.05
USD
- -
- -
ISIN
AU000000NOX9
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-85.00
76.60
5Y
-46.43
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Gisela Mautner
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Tower A, The Zenith Chatswood NSW Australia 2067
- IPO Date
- Jan 29, 2020
- Website
- noxopharm.com
- Similar Companies
- Business
- Noxopharm Limited (ASX:NOX; OTC:NOXOF) is an Australian clinical-stage biotechnology company focused on discovering and developing novel oncology and anti-inflammatory drug candidates, as well as proprietary technologies to enhance mRNA vaccines; its core platforms include Chroma™ for oncology applications such as the CRO-67 dual-cell therapy targeting pancreatic cancer and associated stromal barrier cells, and Sofra™ for inflammation, autoimmunity, and mRNA vaccine enhancement via candidates like SOF-VAC™, which reduces inflammatory side effects such as fever and fatigue in mRNA-based therapeutics including COVID vaccines, alongside SOF-XX and SOF-SKN™ for autoimmune diseases like lupus, psoriasis, and chronic inflammation. The company maintains a major shareholding in US-listed Nyrada Inc. (ASX:NYR), which develops drugs for cardiovascular and neurological disorders. Founded in 2015 and headquartered in Sydney, New South Wales, Noxopharm conducts operations primarily in Australia through in-house R&D and strategic collaborations with institutions including the Hudson Institute of Medical Research and UNSW Sydney. In recent developments, Noxopharm received a NSW Government grant in November 2025 to support its UNSW collaboration, announced preclinical progress and new clinical trial preparations for SOF-SKN™ targeting chronic inflammatory diseases in September 2025, secured convertible note funding, entered multiple material transfer agreements to explore commercial opportunities, generated nearly $2.5 million in non-dilutive funds from Nyrada share sales, discontinued its Veyonda® DARRT-2 and CEP-2 clinical trials in 2023 to prioritize preclinical platforms amid patient recruitment challenges and cost efficiencies, reduced headcount by 40% as part of a strategic operational restructuring, and continues supplying Veyonda® for the investigator-initiated IONIC trial while advancing robust intellectual property protections around its assets.